We will continue our Developmental Research Program which includes directives to support both investigator initiated pilot project application as well as targeted research in specific areas that are highly likely to advance the translational research goals of the SPORE. The total budget for the Developmental Research Program will be $200,000 of which approximately 75% will be allocated for pilot project funding and 25% for target research initiatives. Priorities for pilot project selection include those that are truly creative, highly innovative, and are of the highest possible scientific quality. These projects should also complement the long-term research goals of the SPORE and contribute toward the success of our translational research objectives. The targeted research priorities include highly select experimental or clinical initiatives that address a specific need in our SPORE program as judged by the Scientific Advisory Committee. The Developmental Research Program has thus far proved critical in the growth and expansion of our SPORE research program and has accelerated progress toward our specific translational objectives. Through pilot project funding, highly talented senior-level investigators have been recruited to focus on translational research in prostate cancer. In addition, this program has played an important role in recruiting promising junior-level faculty to the Scott Department of Urology and to other Baylor departments. During our initial SPORE-funding period, pilot project awards have been successfully converted by many investigators into substantial peer reviewed research grant awards, and in some cases, to a leading role within the SPORE. The review mechanism for use of Development Research Funds, which we initiated upon receiving SPORE funding, has been highly successful. The Scientific Advisory Committee, under the direction of Bert W. O'Malley, M.D. has assumed responsibility for evaluating, prioritizing, and awarding developmental research funding. We will maintain the basic structure of the committee, which will also remain under the direction of Dr. O'Malley. But because of the increasing responsibilities and complexity of the decisions facing of Scientific Advisory Committee, we have added two additional members. We are highly optimistic regarding the function of our Developmental Research Program and anticipate that it will continue to play a fundamental role in the success of our SPORE.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
3P50CA058204-06S1
Application #
6296079
Study Section
Project Start
1998-09-30
Project End
1999-05-31
Budget Start
1997-10-01
Budget End
1998-09-30
Support Year
6
Fiscal Year
1998
Total Cost
Indirect Cost
Name
Baylor College of Medicine
Department
Type
DUNS #
074615394
City
Houston
State
TX
Country
United States
Zip Code
77030
Olar, Adriana; He, Dandan; Florentin, Diego et al. (2014) Biological correlates of prostate cancer perineural invasion diameter. Hum Pathol 45:1365-9
Olar, Adriana; He, Dandan; Florentin, Diego et al. (2014) Biologic correlates and significance of axonogenesis in prostate cancer. Hum Pathol 45:1358-64
Sonpavde, Guru; Wang, Mingjun; Peterson, Leif E et al. (2014) HLA-restricted NY-ESO-1 peptide immunotherapy for metastatic castration resistant prostate cancer. Invest New Drugs 32:235-242
Nakka, Manjula; Agoulnik, Irina U; Weigel, Nancy L (2013) Targeted disruption of the p160 coactivator interface of androgen receptor (AR) selectively inhibits AR activity in both androgen-dependent and castration-resistant AR-expressing prostate cancer cells. Int J Biochem Cell Biol 45:763-72
Ding, Yi; He, Dandan; Florentin, Diego et al. (2013) Semaphorin 4F as a critical regulator of neuroepithelial interactions and a biomarker of aggressive prostate cancer. Clin Cancer Res 19:6101-11
Feng, Shu; Dakhova, Olga; Creighton, Chad J et al. (2013) Endocrine fibroblast growth factor FGF19 promotes prostate cancer progression. Cancer Res 73:2551-62
Yang, Feng; Zhang, Yongyou; Ressler, Steven J et al. (2013) FGFR1 is essential for prostate cancer progression and metastasis. Cancer Res 73:3716-24
Yang, Guang; Goltsov, Alexei A; Ren, Chengzhen et al. (2012) Caveolin-1 upregulation contributes to c-Myc-induced high-grade prostatic intraepithelial neoplasia and prostate cancer. Mol Cancer Res 10:218-29
Sonpavde, Guru; Thompson, Timothy C; Jain, Rajul K et al. (2011) GLIPR1 tumor suppressor gene expressed by adenoviral vector as neoadjuvant intraprostatic injection for localized intermediate or high-risk prostate cancer preceding radical prostatectomy. Clin Cancer Res 17:7174-82
Wang, Jianghua; Cai, Yi; Shao, Long-Jiang et al. (2011) Activation of NF-{kappa}B by TMPRSS2/ERG Fusion Isoforms through Toll-Like Receptor-4. Cancer Res 71:1325-33

Showing the most recent 10 out of 262 publications